Glioblastoma Research News for the Third Two Months of 2022

This is the fifteenth article of the project which aims to report news (every two months) of the possible treatments for glioblastoma multiforme.
Below is the news that we considered most significant. As for the previous articles in the series, each news will be preceded by the original title with a link to the source and followed by a short comment. The criterion by which news is chosen is always to include in general only news related to research in the clinic, unless the research potential for the treatment of glioblastoma is not really significant.

DCVax-L Phase 3 Clinical Trial Results – Video     
The results presented in this video are outstanding. This is a more than 200% increase in the 5-year survival rate for newly diagnosed glioblastoma and 30-month survival for recurrent glioblastoma. We have already dedicated an article to this news. 

GT Medical Technologies Announces the Presentation of Clinical Data on GammaTile® Therapy in the Treatment of Recurrent Glioblastomas at the 2022 American Association of Neurological Surgeons Scientific Meeting
Very encouraging results. For patients with recurrent glioblastoma with methylated MGMT, overall survival reached 37 months. For patients with unmethylated MGMT, survival was 20 months. GammaTiles are implantable platelets that release radiation into the tumor bed. The website https://gammatile.com/findatreatmentcenter/ lists the centres that can do this treatment. 

Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug
The Korean biotech company expects significant results from its phase 2 clinical trial of the ITI-1000 drug, which will be available by August. In fact, it appears that the median survival rate is 40 months compared to 16 months of the standard of care. The study involved 120 patients.

Clinical Trials of Oncolytic Viruses in Glioblastoma
This is an article that reviews all oncolytic viruses used to treat glioblastoma. Japan has granted limited-time conditional approval of the oncolytic teserpaturev virus, due to a small clinical study involving only 13 patients that showed a 92% 1-year survival for recurrent glioblastoma. The results are being published.

Promising results from the GLORIA study presented at the ASCO 2022 meeting
The phase 1-2 study evaluated the application of NOX-A12 in glioblastoma with unmethylated MGMT with partial resection or with only biopsy. 90% of patients who received NOX-A12 with radiotherapy achieved a reduction in tumor volume, compared with 25% of patients who received standard care. 40% of patients who received NOX-A12 with radiotherapy had a partial response (tumor volume reduction greater than 50%) compared with 10% in a control group who received standard care. In 30% of patients who received NOX-A12 in combination with radiotherapy, one or more secondary lesions completely disappeared. The combination of radiotherapy and NOX-A12 was found to be safe and well tolerated.

There are no other relevant research news. Most of research news were related to pre-clinical studies. A relevant novelty for Glioblastoma.It ODV is that we finally have a scientific committee. In the next few days we will report the names and a brief profile of the experts who are part of it. Best of luck to all those fighting glioblastoma and their caregivers!